Lucid Diagnostics Inc (NAS:LUCD)

Q4 2024 Lucid Diagnostics Inc Earnings Call Transcript

Mar 24, 2025 / 12:30 PM GMT

Release Date Price: $1.5 (-1.32%)

Transcript 8-K10-K

Key Points

Positve

Lucid Diagnostics Inc (LUCD) reported a strong finish to 2024 with significant advancements in sales channels and reimbursement milestones.
The company achieved a record quarterly test volume of over 4,000 tests, surpassing their target of 2,500 to 3,000 tests per quarter.
Lucid Diagnostics Inc (LUCD) secured its first positive commercial insurance coverage policy with Highmark Blue Cross Blue Shield of New York, setting a precedent for future engagements with commercial payers.
The National Comprehensive Cancer Network (NCCN) included a section on screening for esophageal pre-cancer in their clinical practice guidelines, aligning with existing guidelines and supporting the use of non-endoscopic biomarker testing.
The company strengthened its balance sheet with a long-term debt refinancing and a registered direct common stock offering, extending their financial runway past upcoming key reimbursement milestones.

Negative

Revenue for the fourth quarter was $1.2 million, which was relatively flat compared to recent quarters.
The company's quarterly burn rate was $10.1 million, although this was lower than the average burn rate for the four preceding quarters.
The effective average selling price (ASP) per test was lower than expected, around $300, due to timing of payments and elongated collection periods.
A significant portion of reimbursement claims are still being adjudicated, with some claims being denied as not medically necessary or requiring prior authorization.
The company is still in the early stages of its reimbursement process, recognizing revenue only upon actual cash collections rather than when the test report is delivered.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LUCD.OQ - Lucid Diagnostics Inc
Q4 2024 Lucid Diagnostics Inc Earnings Call
Mar 24, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Lucid Diagnostics 4th quarter 2024 business update conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call, you require immediate assistance, please press 0 for the operator. Please note that this event is being recorded. I would now like To turn the conference over to Matt Riley, Lied Diagnostics, senior director of Investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.